Evidence map›Paper›PMID 38352727›Full record

ArticleVaccine: X2024

Compatible co-administration of BioThrax® vaccine and ciprofloxacin-Results of a randomized open-label drug-vaccine interaction trial.

David Cassie, Janice Longstreth, Robert Hopkins, Ericka Hunter-Stitt, Bojan Drobic, Melisa Bellani

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01753115 (A Study of The Effects of Co-Administering Ciprofloxacin and BioThrax on the Pharmacokinetics of Ciprofloxacin in Healthy Adults), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01753115 phase2completednot on this map

A Study of The Effects of Co-Administering Ciprofloxacin and BioThrax on the Pharmacokinetics of Ciprofloxacin in Healthy Adults

TypeinterventionalSponsorEmergent BioSolutionsRan2012 to 2013Enrolled154ConditionsAnthraxArmsBioThrax, Ciprofloxacin
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

David CassieEmergent BioSolutions Canada Inc., 155 Innovation Drive, Winnipeg, MB R3T 5Y3, Canada.
Janice LongstrethThe Institute for Global Risk Research, LLC, 9119 Kirkdale Road, Suite 200, Bethesda, MD 20817, USA.
Robert HopkinsAdaptive Phage Therapeutics, 708 Quince Drive, Gaithersburg, MD 20878, USA.
Ericka Hunter-StittEmergent BioSolutions Inc., 400 Professional Drive, Gaithersburg, MD 20879, USA.
Bojan DrobicEmergent BioSolutions Canada Inc., 155 Innovation Drive, Winnipeg, MB R3T 5Y3, Canada.
Melisa BellaniEmergent BioSolutions Canada Inc., 155 Innovation Drive, Winnipeg, MB R3T 5Y3, Canada.
Emergent BioSolutions (Canada) · CAEmergent BioSolutions (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recommended treatment for post-exposure prophylaxis (PEP) following known/suspected exposure to

Indexed as

AnthraxBioThrax®Drug-vaccine interaction, ciprofloxacinPost-exposure prophylaxisVaccine

Identifiers

PMID38352727
PMCPMC10863310
OpenAlexW4390650529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.